CCP-RIZATRIPTAN ODT TABLET (ORALLY DISINTEGRATING)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

Pieejams no:

CELLCHEM PHARMACEUTICALS INC.

ATĶ kods:

N02CC04

SNN (starptautisko nepatentēto nosaukumu):

RIZATRIPTAN

Deva:

10MG

Zāļu forma:

TABLET (ORALLY DISINTEGRATING)

Kompozīcija:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

6

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE SEROTONIN AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0137841002; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2023-08-03

Produkta apraksts

_CCP-Riztriptan ODT _
_Page 1 of 34_
PRODUCT MONOGRAPH
PR
CCP-RIZATRIPTAN ODT
Rizatriptan Benzoate Orally Disintegrating Tablets
5 mg and 10 mg Rizatriptan (as Rizatriptan Benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Date of Revision:
June 19, 2017
CellChem Pharmaceuticals Inc.
30 Concourse Gate, Unit 1
Ottawa, Ontario
K2E 7V7
Control #
205269
_CCP-Riztriptan ODT _
_Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
................................................................................3
INDICATIONS AND CLINICAL USE
......................................................................................3
CONTRAINDICATIONS
...........................................................................................................3
WARNINGS AND PRECAUTIONS
..........................................................................................4
ADVERSE REACTIONS
..........................................................................................................10
DRUG INTERACTIONS
..........................................................................................................16
DOSAGE AND ADMINISTRATION
......................................................................................18
OVERDOSAGE
.........................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
....................................................................19
STORAGE AND STABILITY
..................................................................................................22
SPECIAL HANDLING INSTRUCTIONS
...............................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................................23
PART II: SCIENTIFIC INFORMATION
..............................................................................
27
PHARMACEUTICAL INF